SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2. [PDF]
Cho HJ +19 more
europepmc +1 more source
Use of whole blood platelet lumi‐aggregometry to optimize anti‐platelet therapy in patients with chronic myeloproliferative disorders [PDF]
A. Manoharan +2 more
openalex +1 more source
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
A. Pardanani +13 more
semanticscholar +1 more source
[The role of AKT inhibitors combined with Ruxolitinib in ameliorating myeloproliferative disorders in mice with CALR gene mutations]. [PDF]
Zhang LW +6 more
europepmc +1 more source
In vitro cell growth in neonates with Down's syndrome and transient myeloproliferative disorder [PDF]
JF Denegri +4 more
openalex +1 more source
The Association Between Janus Kinase 2 and Factor V Leiden Mutations and Thrombotic Complications in Patients With Myeloproliferative Disorders: A Study From Saudi Arabia. [PDF]
Sayed WS +4 more
europepmc +1 more source
292 Morgana Haploinsufficiency Induces a Myeloproliferative Disorder Like-chronic Myeloid Leukemia
Augusta Di Savino +9 more
openalex +1 more source
Four Cases of Myeloproliferative Disorders Associated With Down Syndrome: Distinguishing ML-DS From TAM-DS: Distinguishing TAM-DS and ML-DS: Report of 4 Cases. [PDF]
Boumeghar K +9 more
europepmc +1 more source
Qualitative platelet defects in chronic myeloproliferative disorders: Evidence for reduced ATP secretion [PDF]
Eva Löfvenberg, Torbjörn K. Nilsson
openalex +1 more source

